25th Jun 2015 12:14
LONDON (Alliance News) - Ergomed PLC said Thursday that it has been selected by NASDAQ-listed Aeterna Zentaris Inc to manage a new phase 3 clinical study of Aeterna's product Macrilen for evaluating adult growth hormone deficiency.
The study will test will be conducted as a two-way crossover study with the insulin tolerance test as the benchmark comparator, and will consist of patients with a medical history documenting risk factors for adult growth hormone deficiency.
"We are delighted that Aeterna Zentaris has selected us to manage their confirmatory study of Macrilen. We have a strong and deep working relationship the Aeterna Zentaris scientific staff and hold them in the highest regard," said Chief Executive Officer Miroslav Reljanovic in a statement.
Shares in Ergomed are trading up 2.6% at 171.80 pence Thursday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
ERGO.L